摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-溴吲哚-2-羧酸 | 16732-64-2

中文名称
4-溴吲哚-2-羧酸
中文别名
4-溴吲哚-2-甲酸;4-溴-1H-吲哚-2-羧酸
英文名称
4-bromo-1H-indole-2-carboxylic acid
英文别名
4-bromoindole-2-carboxylic acid;4-Brom-indol-2-carbonsaeure
4-溴吲哚-2-羧酸化学式
CAS
16732-64-2
化学式
C9H6BrNO2
mdl
MFCD02664468
分子量
240.056
InChiKey
SXFVRIRMDXONCT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    263 °C
  • 沸点:
    470.9±25.0 °C(Predicted)
  • 密度:
    1.838±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    53.1
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335

SDS

SDS:ba64ed8bb5440ccde014d408ab722414
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-Bromo-1H-indole-2-carboxylic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-1H-indole-2-carboxylic acid
CAS number: 16732-64-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H6BrNO2
Molecular weight: 240.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Plieninger, Chemische Berichte, 1955, vol. 88, p. 370,373
    摘要:
    DOI:
  • 作为产物:
    描述:
    2-溴-6-硝基甲苯盐酸potassium ethoxide 、 iron(II) sulfate 作用下, 以 乙醇 为溶剂, 生成 4-溴吲哚-2-羧酸
    参考文献:
    名称:
    Indoline analogs of idazoxan: potent .alpha.2-antagonists and .alpha.1-agonists
    摘要:
    The synthesis and alpha-adrenergic activity of a series of substituted 2-imidazolinylindolines are described. Substitution in the indoline ring generated compounds with a spectrum of adrenoceptor antagonist/agonist profiles that proved sensitive to both the nature and position of the substituent. Many of the derivatives possess greater presynaptic antagonist potency than the corresponding benzodioxan 1, dihydrobenzofuran 2, and indan 3 analogues; however, this alpha 2-antagonism is often accompanied by alpha 1-agonist activity. It was not possible to separate alpha 2-antagonist from alpha 1-agonist properties in this series. Compounds of most interest proved to be the N-ethyl 6, 5-chloro-N-methyl 18, and 5-chloro-N-ethyl 23 derivatives, all being potent alpha 2-antagonists and alpha 1-agonists. Substitution at the 4- and 7-position of the indoline ring generally gave compounds with nonselective agonist properties.
    DOI:
    10.1021/jm00400a009
点击查看最新优质反应信息

文献信息

  • MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME
    申请人:Barany Francis
    公开号:US20140194383A1
    公开(公告)日:2014-07-10
    Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.
    本发明描述了在水中介质中与一个、两个、三个或更多其他单体接触时能够形成具有生物学用途的多聚体的单体。在一方面,这样的单体可能能够在水介质中(例如,体内)与另一个单体结合形成多聚体(例如,二聚体)。考虑的单体可能包括一个配体部分、一个连接元素和一个连接器元素,连接器元素连接配体部分和连接元素。在水介质中,这样的考虑单体可能通过每个连接元素相互连接,因此可能能够实质上同时调节一个或多个生物分子,例如,调节蛋白质上的两个或多个结合域,或者调节不同蛋白质上的结合域。
  • [EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS
    申请人:FOGHORN THERAPEUTICS INC
    公开号:WO2021155320A1
    公开(公告)日:2021-08-05
    The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
    本公开涉及用于治疗BAF复合物相关疾病的化合物。
  • [EN] NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)<br/>[FR] NOUVEAUX INDOLE-2-CARBOXAMIDES ACTIFS CONTRE LE VIRUS DE L'HÉPATITE B (VHB)
    申请人:AICURIS GMBH & CO KG
    公开号:WO2020221826A1
    公开(公告)日:2020-11-05
    The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.
    本发明一般涉及新型抗病毒药剂。具体地,本发明涉及能够抑制乙型肝炎病毒(HBV)编码的蛋白质或干扰HBV复制周期功能的化合物,包括这种化合物的组合物,抑制HBV病毒复制的方法,治疗或预防HBV感染的方法,以及制备这些化合物的工艺和中间体。
  • Integrin expression inhibitors
    申请人:——
    公开号:US20040018192A1
    公开(公告)日:2004-01-29
    The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. 1 In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR 4b R 5b ) m b — (wherein R 4b and R 5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and m b means an integer of 1 or 2); R 1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.
    本发明提供了一种整合素表达抑制剂,以及基于整合素抑制作用的用于治疗动脉硬化、银屑病、癌症、视网膜血管生成、糖尿病视网膜病变或炎症性疾病的药剂、抗凝剂或癌症转移抑制剂。即提供了一种包含以下式(I)所表示的磺胺化合物、其药理学上可接受的盐或其水合物作为活性成分的整合素表达抑制剂。 在该式中,B表示一个C6-C10芳基环或6-至10成员杂芳基环,可能具有取代基,并且环的一部分可能是饱和的;K表示一个单键,-CH═CH-或-(CR 4b R 5b ) m b -(其中R 4b 和R 5b 相同或不同,各自表示氢原子或C1-C4烷基;m b 表示1或2的整数);R 1 表示氢原子或C1-C6烷基;Z表示一个单键或-CO-NH-;R表示一个C6-C10芳基环或6-至10成员杂芳基环,可能具有取代基,并且环的一部分可能是饱和的,分别。
  • Structure-based discovery of 1H-indole-2-carboxamide derivatives as potent ASK1 inhibitors for potential treatment of ulcerative colitis
    作者:Shaohua Hou、Xiping Yang、Yu Tong、Yuejing Yang、Quanwei Chen、Boheng Wan、Ran Wei、Yuchen Wang、Yanmin Zhang、Bo Kong、Jianhang Huang、Yadong Chen、Tao Lu、Qinghua Hu、Ding Du
    DOI:10.1016/j.ejmech.2020.113114
    日期:2021.2
    compound 19 with a novel indole-2-carboxamide hinge scaffold. Compound 19 displays potent anti-ASK1 kinase activity and stronger inhibitory effect on ASK1 in AP1-HEK293 cells than previously described ASK1 inhibitor GS-4997. Besides improved in vitro activity, compound 19 also exhibits an appropriate in vivo PK profile. In a dextran sulfate sodium (DSS)-induced mouse model of ulcerative colitis (UC), compound
    凋亡信号调节激酶1(ASK1)是丝裂原激活的蛋白激酶(MAPK)家族的成员,与许多人类疾病有关。在这里,我们描述了命中化合物7的结构优化,并进行了进一步的结构-活性关系(SAR)研究,从而开发了带有新型吲哚-2-羧酰胺铰链支架的化合物19。与先前描述的ASK1抑制剂GS-4997相比,化合物19在AP1-HEK293细胞中显示出强大的抗ASK1激酶活性和对ASK1的更强抑制作用。除了改善体外活性外,化合物19还具有适当的体内活性PK配置文件。在右旋糖酐硫酸钠(DSS)诱导的溃疡性结肠炎(UC)小鼠模型中,化合物19显示出显着的抗UC功效,并显着减轻了DSS诱导的体重减轻,结肠缩短,疾病活动指数(DAI)升高和炎症结肠组织中的细胞浸润。从机理上讲,化合物19抑制ASK1-p38 / JNK信号通路的磷酸化,并抑制炎症细胞因子的过表达。这些发现共同表明,ASK1抑制剂可以潜在地用作UC的治疗策略。
查看更多

同类化合物

(Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (R)-(+)-5'-苄氧基卡维地洛 (R)-卡洛芬 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (3Z)-3-(1H-咪唑-5-基亚甲基)-5-甲氧基-1H-吲哚-2-酮 (3Z)-3-[[[4-(二甲基氨基)苯基]亚甲基]-1H-吲哚-2-酮 (3R)-(-)-3-(1-甲基吲哚-3-基)丁酸甲酯 (3-氯-4,5-二氢-1,2-恶唑-5-基)(1,3-二氧代-1,3-二氢-2H-异吲哚-2-基)乙酸 齐多美辛 鸭脚树叶碱 鸭脚木碱,鸡骨常山碱 鲜麦得新糖 高氯酸1,1’-二(十六烷基)-3,3,3’,3’-四甲基吲哚碳菁 马鲁司特 马来酸阿洛司琼 马来酸替加色罗 顺式-ent-他达拉非 顺式-1,3,4,4a,5,9b-六氢-2H-吡啶并[4,3-b]吲哚-2-甲酸乙酯 顺式-(+-)-3,4-二氢-8-氯-4'-甲基-4-(甲基氨基)-螺(苯并(cd)吲哚-5(1H),2'(5'H)-呋喃)-5'-酮 靛红联二甲酚 靛红磺酸钠 靛红磺酸 靛红乙烯硫代缩酮 靛红-7-甲酸甲酯 靛红-5-磺酸钠 靛红-5-磺酸 靛红-5-硫酸钠盐二水 靛红-5-甲酸甲酯 靛红 靛玉红3'-单肟5-磺酸 靛玉红-3'-单肟 靛玉红 青色素3联己酸染料,钾盐 雷马曲班 雷莫司琼杂质13 雷莫司琼杂质12 雷莫司琼杂质 雷替尼卜定 雄甾-1,4-二烯-3,17-二酮 阿霉素的代谢产物盐酸盐 阿贝卡尔 阿西美辛叔丁基酯 阿西美辛 阿莫曲普坦杂质1 阿莫曲普坦 阿莫曲坦二聚体杂质 阿莫曲坦 阿洛司琼杂质